This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Asarina Pharma Valuation

Is ASAP undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ASAP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ASAP's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ASAP's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ASAP?

Key metric: As ASAP is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for ASAP. This is calculated by dividing ASAP's market cap by their current book value.
What is ASAP's PB Ratio?
PB Ratio	0.4x
Book	SEK 1.65m
Market Cap	SEK 633.96k

ASAP key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does ASAP's PB Ratio compare to its peers?

The above table shows the PB ratio for ASAP vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	1.1x
PHARM Pharmiva	0.6x	n/a	SEK 9.7m
DANCAN DanCann Pharma	1.3x	n/a	DKK 17.9m
STABL Stayble Therapeutics	1.9x	n/a	SEK 23.0m
EEVIA Eevia Health Oyj	0.5x	n/a	SEK 14.4m
ASAP Asarina Pharma	0.4x	n/a	SEK 634.0k

Price-To-Book vs Peers: ASAP is good value based on its Price-To-Book Ratio (0.4x) compared to the peer average (1.5x).

Price to Book Ratio vs Industry

How does ASAP's PB Ratio compare vs other companies in the SE Pharmaceuticals Industry?

5 Companies	Price / Book	Estimated Growth	Market Cap
Industry Avg.	3.1x	73.2%
ASAP Asarina Pharma	0.4x	n/a	US$61.78k
KDEV Karolinska Development	0.2x	5.8%	US$25.46m
EEVIA Eevia Health Oyj	0.5x	n/a	US$1.30m

5 Companies		Estimated Growth	Market Cap
Industry Avg.	3.1x	73.2%
ASAP Asarina Pharma	0.4x	n/a	US$61.78k

No more companies

Price-To-Book vs Industry: ASAP is good value based on its Price-To-Book Ratio (0.4x) compared to the Swedish Pharmaceuticals industry average (4.9x).

Price to Book Ratio vs Fair Ratio

What is ASAP's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ASAP PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	0.4x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ASAP's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

PMD Device Solutions

SEK 35.3m

A digital medical device company, develops and sells respiratory monitoring solutions in Ireland.

PMDS

SEK 1.36

-8.1%

n/a

AstraZeneca

UK£162.4b

A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.

AZN

UK£1,462.00

5.0%

8.2%

Swedish Orphan Biovitrum

SEK 99.6b

An integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia.

SOBI

SEK 290.00

-2.7%

14.5%